PFE ends deal with SGMO for hemophilia A gene therapy candidate. NVS' gene therapy for SMA meets goal in study.

Novartis’ NVS phase III study showed a positive risk-benefit profile of an investigational gene therapy candidate, intrathecal onasemnogene abeparvovec (OAV101 IT), for treating spinal muscular ...

Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Below is Validea's guru fundamental report for PFIZER INC (PFE). Of the 22 guru strategies we follow, PFE rates highest using our Shareholder Yield Investor model based on the published strategy ...

We like to see robust dividend yields, but that doesn't matter if the payment isn't sustainable. Based on the last payment, the company wasn't making enough to cover what it was paying to ...

The first human bird flu death in the US has Moderna's vaccine development in focus for investors this week. Pfizer (PFE) reachead $26.91 at the closing of the latest trading day, reflecting a -0.83% ...

CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and ...

Shopify is the IBD Stock of the Day. The e-commerce company has several initiatives underway that could provide upside for ...

GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing ...